NCT07878130Not yet recruitingPhase 2
An Investigation of Mechanisms That Underly Paranoia in Behaviour and Brain That Can Inform Clinical Diagnoses That Include Paranoid Symptoms.
Bridging the Neurocomputational Explanations of Paranoia: From Cognition to Clinic
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
The study team is studying how delta-9-tetrahydrocannabinol (THC) - the component of cannabis that is responsible for "getting people feeling high" - influences how people think about the behaviour of others and a variety of other experiences. The study team is investigating these processes in healthy adults. The study team uses computer-based tasks and questionnaires to understand how people make conclusions about other people's intentions under different circumstances. In this study, the study team uses a placebo-controlled within-participant study design with three different conditions: (i) 1mg/ml THC administration, (ii) 2mg/ml THC administration, and (iii) placebo (Saline) administration, all via an intravenous IV. The study is within-participants, meaning that every participant will experience all three conditions. The study is double blind, meaning that neither the researcher nor the participant will know what condition they will be in on a given study visit. The sequence of conditions is balanced across participants.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 18 Sept 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- King's College London
- NCT number
- NCT07878130
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 100
- From 1 Nov 2026 to the primary completion date, 30 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having ever been treated with an anti-psychotic or anti-depressant medication
- Currently taking psychotropic medication
- Having a positive urine drug screen (any drug) at any of the study visits (baseline and experimental sessions)
- Having participated in a drug study within the last 30 days
Other illness
- Having a past or present major mental illness
- Having a past or present major physical illness (e.g. respiratory or heart condition)
- Having a past or present substance use disorder
- Having a first degree relative (parent or sibling) with psychotic illness
- Having a known sensitivity or allergy towards cannabis or Lorazepam
Other
- Not having a normal ECG reading at screening visit
- Having screening blood tests outside normal ranges, determined to be clinically significant
- Having self-reported use of alcohol within 24h of an experimental visit or a positive alcohol breath test
- Being pregnant or planning pregnancy or lactating in women
- Discovery of significant abnormality during physical examination at screening visit
- Is using cannabis (defined as days in which cannabis is used recreationally) more often than once per week on average over the last 12 months.
- Smoking more than 4 cigarettes or vapes per week.
- Drinking more than 4 units (100ml) of coffee per day.
- Any past use of synthetic cannabinoids
- Having a score of 5 or more on the Fagerstrom Nicotine Dependence Questionnaire
- Having a BMI classified as obese or underweight (below 18 or over 30)
Who the study is looking for
- Have used cannabis at least once in the past
- Willing and able to provide written informed consent
- Willing to provide blood samples for screening purposes
- Agrees to use highly effective methods of contraception for the duration of the study and for 3 months after the final study visit (see Contraception below)
- Be able to understand the information sheet
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| King's College London Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.